Status:
COMPLETED
Effect of Magnesium on Dose of Rocuronium for Deep Neuromuscular Blockade
Lead Sponsor:
Seoul National University Bundang Hospital
Conditions:
Magnesium Sulfate Causing Adverse Effects in Therapeutic Use
Neuromuscular Blockade
Eligibility:
MALE
20-80 years
Phase:
NA
Brief Summary
It is well known that magnesium enhances the effect of neuromuscular blocking agents such as rocuronium. However, it is not known how much magnesium can reduce neuromuscular blocking agents in maintai...
Detailed Description
It is well known that magnesium potentiate the effect of neuromuscular blocking agents. It prolonged the duration of rocuronium and reduces the onset time of rocuronium. Magnesium acts on motor end pl...
Eligibility Criteria
Inclusion
- Patients who undergo elective robot assisted radical prostatectomy, between 20 and 80 years with a American Society of Anesthesiologists physical status classification of I or II
Exclusion
- Conduction abnormalities in preoperative EKG such as Atrioventricular block, sinus pause
- Glomerular filtration rate \<60ml/min/1.73m2
- Allergy to rocuronium, sugammadex, magnesium
- Medications that interfered with muscle activity
- Neuromuscular disease
- Hypermagnesemia
Key Trial Info
Start Date :
April 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2019
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04013243
Start Date
April 26 2019
End Date
July 30 2019
Last Update
December 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620